Chest Infections: Chest Infections: Bacterial |

In Vitro Activities of Nine Candidate Antimicrobials Against Clinical Isolated Stenotrophomonas Maltophilia and a Time-Killing Study FREE TO VIEW

Chuanqi Wei
Author and Funding Information

Chinese People’s Liberation Army General Hospital, Beijing, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A98. doi:10.1016/j.chest.2016.02.103
Text Size: A A A
Published online

SESSION TITLE: Chest Infections: Bacterial

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: The optimal therapy for infections caused by Stenotrophomonas maltophilia (S. maltophilia) hasn't yet been established. The objective of our study is to evaluate the in vitro activity of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E, ceftazidime and to select for desired antimicrobial combinations against clinical isolated S. maltophilia.

METHODS: The agar dilution method was used to test susceptibility of those candidate antimicrobials and time-killing method was carried out to evaluate the combination effect of potential drugs.

RESULTS: The susceptibility to SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E and ceftazidime were 93.75%, 95%, 83.8%, 80%, 76.25%, 76.25%, 37.5%, 22.5% and 20% against 80 clinical consecutively isolated strains, respectively. Minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, polymyxin E, chloramphenicol and ceftazidime susceptibility were 86.4%, 72.7%, 40.9%, 40.9%, 50%, 22.7%, 13.6% and 4.5% against 22 SXT-resistant strains, respectively. In the time-killing study, synergy was found in SXT plus moxifloxacin and minocycline plus moxifloxacinat when moxifloxacin MICs≤4 µg/ml. The remaining combinations demonstrated indifferent at clinically relevant static antibiotic concentrations. No antagonisms were found in these combinations

CONCLUSIONS: Minocycline and SXT may be considered as first line choices while tigecycline, moxifloxacin, levofloxacin and ticarcillin-clavulanate may serve as second line drugs in S. maltophilia infections. It may be not proper to consider ceftazidime, colistin and chloramphenicol as choices against S. maltophilia. SXT plus moxifloxacin and minocycline plus moxifloxacin may be proper combinations in serious infections

CLINICAL IMPLICATIONS: Our studies provide some references for doctors to choose proper drugs and combinations in clinical settings.

DISCLOSURE: The following authors have nothing to disclose: Chuanqi Wei

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543